Sonesta International Hotels concludes a sweeping multi-year renovation initiative, injecting modern amenities and design into properties from New York to Kaua'i, as the company sharpens its competitive edge in the hospitality sector.
Oracle announces plans to raise up to $50 billion in 2026 through debt and equity to massively expand its cloud data centers, aiming to meet surging demand from AI leaders like Nvidia, OpenAI, and xAI.
Auna S.A. (NYSE:AUNA) saw its market value shed $55 million last week, with its largest shareholder group—private equity firms—absorbing the heaviest losses. We analyze the ownership structure and what it means for the Latin American healthcare provider's future.
The European CE Mark under the stringent MDR has been granted for Cynosure Lutronic's innovative fractional resurfacing system, designed to improve safety and patient comfort through advanced cooling and precision technology.
Eastern Bankshares (EBC) concludes a transformative year, reporting full-year 2025 results, affirming its dividend, and completing a share repurchase. The moves have propelled its stock, raising questions about its valuation amidst a shifting banking landscape.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
A deep dive into the conflicting signals from Church & Dwight's stock valuation. While a discounted cash flow model suggests a significant discount, its premium P/E ratio tells a different story, leaving investors to weigh pricing power against market expectations.
A deep dive into Truist Financial's valuation suggests its current share price may not fully reflect its underlying earnings power and book value, presenting a potential opportunity for investors.
A new valuation model suggests Eos Energy Enterprises' stock could be significantly undervalued, presenting a potential opportunity for investors amid a shifting energy policy landscape.
A look back at 2016's recurring bills reveals a stark financial truth: small, consistent savings on expenses like cable, cell plans, or insurance, when invested, could have yielded a significant nest egg by today.
In turbulent markets, volatility presents both opportunity and peril. We analyze three stocks with high betas: one showing potential in the freelance revolution, while two others face significant headwinds despite their roles in infrastructure and auto tech.
Amid market turbulence, certain stocks exhibit extreme price swings coupled with underlying fundamental concerns. We examine three such names where caution may be warranted.
While sell-side analysts tout significant upside for Q2 Holdings, Teladoc Health, and Caleres, a closer look reveals potential pitfalls and valuation concerns that warrant caution from discerning investors.
The global packaging giant has successfully completed its court-supervised restructuring, slashing its debt burden by €1.3 billion and securing €349 million in fresh capital to stabilize operations under new ownership led by Redwood Capital Management.
Gold and silver prices plunged to multi-year lows as markets reacted to former Fed Governor Kevin Warsh's nomination, signaling a potential shift toward a more hawkish central bank policy and stronger dollar.
Nominee Kevin Warsh's desire to aggressively shrink the Federal Reserve's multi-trillion dollar holdings collides with a financial system now structurally dependent on ample liquidity, making rapid contraction a high-risk endeavor, analysts say.
Following a strategic partnership with Singapore's GIC, Realty Income (NYSE: O) is poised for a transformative year. Analysts forecast further international growth, portfolio diversification into new property verticals, and a potential rebound in share performance as catalysts align.
A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
After a punishing year for many restaurant stocks, a seismic shift is underway. As inflation-weary diners become more selective, value and experience are trumping category labels, driving a surprising resurgence in casual dining while challenging the fast-casual model.
